MedGenome develops sputum-based test to flag drug resistance in TBOctober 8, 2019
MedGenome Labs has developed ‘Spit Seq’, the first whole genome sequencing based test that can provide a detailed analysis of every single drug resistance-related mutation present in any tuberculosis bacteria contained in a sputum sample.
The test will enable clinicians to quickly and accurately prescribe the most effective drug to a tuberculosis patient.
The test is based on whole genome sequencing of Mycobacterium tuberculosis (MTB), the TB causing bacteria, to assess the mutations in the bacteria’s genome, and allows the clinician to determine which drugs will work for a patient.
It has been validated with over 100 samples where it recorded with 100 percent sensitivity and 98.04 percent specificity when compared with Line Probe Assay (LPA).
Typically, the process of analyzing drug resistance is very long, leading to delays in treatment for MDR-TB patients.
“Direct whole genome sequencing reveals information on drug resistance mutations for all anti-TB drugs in a matter of 10 days. Soon, this technology will help in optimizing the precise management of an MDR-TB patients”, stated Dr Camilla Rodrigues, P D Hinduja Hospital and Medical Research Centre, Mumbai.
“Spit Seq is a massive breakthrough that can help millions. This particular test not only brings accurate results but also saves a lot of time where TB treatment is concerned,” said Dr VL Ramprasad, COO, MedGenome Labs.